Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading ...

Summit Therapeutics (NASDAQ: SMMT) was one of the stars of the biotech industry. The company's shares soared following a ...

Summit Therapeutics (NASDAQ:SMMT) stock spikes as Citi upgrades the company, citing its lead asset ivonescimab, developed ...

NASDAQ:SMMT opened at $20.60 on Wednesday. The stock has a market cap of $15.20 billion, a PE ratio of -73.57 and a beta of -1.04. The stock’s 50-day moving average is $20.49 and its two-hundred ...

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” ...

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (BMV:SMMT) from Neutral to Buy. Baker Bros. Advisors holds 24,425K shares representing 3.31% ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably ...

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (NasdaqGM:SMMT) from Neutral to Buy. As of March 18, 2025, the average one-year price target for ...